De Aquino JP

Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.

2 preprints · 4 papers · ORCID

PreprintPsilocybin

Who Is Reached by Supervised Psilocybin Services? Oregon Services Versus National Psilocybin Use

Costa GPA, Riggione C, Pittenger C +1

Europe PMC2026
PreprintPsilocybin

Enhancing cGMP signaling with psilocybin reduces head twitch and restructures the synaptic proteome while maintaining antidepressant response

Floris G, Jefferson SJ, Rondeau J +7

Europe PMC2026
ArticlePsilocybin

Psychedelic drugs for the treatment of substance use disorders.

Sofuoglu M, De Aquino JP, MacLean RR

Europe PMC2025
ArticlePsychedelics

From taboo to treatment: The emergence of psychedelics in the management of pain and opioid use disorder.

Weleff J, Nunes JC, Costa GPA +3

Europe PMC2024
ArticleKetamine

Developing non-opioid therapeutics to alleviate pain among persons with opioid use disorder: a review of the human evidence.

Oliveira D, Fontenele R, Weleff J +2

Europe PMC2023
ArticleKetamine

Helpful or Harmful? The Therapeutic Potential of Medications with Varying Degrees of Abuse Liability in the Treatment of Substance Use Disorders.

Martins B, Rutland W, De Aquino JP +4

Europe PMC2022